Drug Name:
DILATRATE-SR Rx
Generic Name and Formulations:
Isosorbide dinitrate 40mg; sust-rel caps.
Company:
Endo Pharmaceuticals
Therapeutic Use:
Indications for DILATRATE-SR:
Prophylaxis and treatment of angina. Not for acute attacks.
Adult:
See full labeling. Allow at least an 18-hour interval daily between doses to avoid development of tolerance. Max 160mg/day.
Children:
Not established.
Contraindications:
Concomitant PDE inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) or riociguat.
Warnings/Precautions:
Recent MI. CHF. Volume depletion. Hypotension. Hypertrophic cardiomyopathy. Monitor standing blood pressure when increasing doses. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Pharmacological Class:
Nitrate.
Interactions:
See Contraindications. Hypotension potentiated with alcohol, other vasodilators.
Adverse Reactions:
Headache, transient lightheadedness, orthostatic hypotension; rare: syncope, angina, rebound hypertension.
How Supplied:
Caps—100
Sign Up for Free e-newsletters
ONA Articles
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer
- Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |